REFRACTORY CANCER
Clinical trials for REFRACTORY CANCER explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CANCER trials appear
Sign up with your email to follow new studies for REFRACTORY CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets hard-to-treat cancers in major clinical trial
Disease control OngoingThis study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help control the cancer. About 350 people with various cancer types, …
Matched conditions: REFRACTORY CANCER
Phase: PHASE2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New immune drug IMA401 takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug called IMA401 in about 95 adults with advanced solid tumors (like lung or head/neck cancer) that came back or didn't respond to prior treatments. IMA401 is a special immune molecule that helps the body's T cells attack cancer cells. The stu…
Matched conditions: REFRACTORY CANCER
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
Tailored cancer therapy tested for patients who've run out of options
Knowledge-focused OngoingThis study explores whether personalized treatment recommendations based on lab tests of a patient's own tumor can be made within 4 weeks for adults with relapsed or refractory cancers who have no standard curative options. Researchers will use drug sensitivity testing and geneti…
Matched conditions: REFRACTORY CANCER
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 18, 2026 12:00 UTC